Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells

Journal of Cardiovascular Pharmacology

Volumn 35, Issue 5, 2000, Pages 749-757

  Goetze, Stephan ^a,b   Kim, Sarah ^a   Xi, Xiao Ping ^a   Graf, Kristof ^a,b   Yang, Dong C ^a   Fleck, Eckart ^b   Meehan, Woerner P ^a   Hsueh, Willa A ^a   Law, Ronald E ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ERK1 2 MAPK; Insulin; Proliferation; Troglitazone; Vascular smooth muscle cells

Indexed keywords

INSULIN; LIGAND; PROSTAGLANDIN; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TROGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL MIGRATION; DNA SYNTHESIS; ENZYME ACTIVITY; GENE EXPRESSION; INSULIN RELEASE; MITOGENESIS; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 0034059395     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200005000-00011     Document Type: Article

References (4)

1. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
2. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
3. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study: The Troglitazone Study Group. J Clin Endocrinol Metab 1998;83:3169-76.
4. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 1997;46:935-42.